by Biospring | Aug 1, 2022 | Advanced Therapy, Biologics, Biomanufacturing, CDMO, Cell and Gene Therapy, CGT, Drug Development, Life Sciences Technology
For a biotech company, discovering a new therapeutic candidate is a years-long, herculean achievement. A crucial question post-discovery is, can the drug be manufactured at scale? Companies must ensure that they can procure enough of a new therapy for clinical trials...
by Biospring | Apr 26, 2022 | Cell and Gene Therapy, Cell Therapy, CGT, Gene Therapy, Kiniciti
We’re pleased to announce our investment in Kiniciti, a Cell and Gene Therapy (“CGT”) aggregator. We’ve had the pleasure of working with Kiniciti over the past year to identify opportunities in the cell and gene therapy market. Biospring’s...
by Biospring | Apr 26, 2022 | Biotech, Cell and Gene Therapy, Cell Therapy, CGT, Gene Therapy, Pharma
What if instead of treating the symptoms of a disease, we could target the source of the disease itself? Cell and Gene Therapy (C>) can do just that. These advanced therapies are the result of decades of research on the building blocks (cells) and blueprints...
